Let me flesh this out because what Sinclair is doing here is actually worth talking through in detail. His lab has been working on these epigenetic aging pathways for years, and the latest MIT Tech Review deep dive reveals he's moving past single-target senescence research toward a truly systemic approach. He wants to develop and test drugs that hit multiple biological targets simultaneously — not just senolytics or metformin alone but combinations designed to reset several aged systems at once in mice models before scaling up. The reasoning is clear: aging is inherently multifacted, so targeting one protein won't fix the whole organism over time, which has been a major limitation of prior work. His team already ran an experiment where they mixed senolytics with metformin and found that combining them was more effective than either alone at reversing age-related phenotypes in mice, which is exactly the kind of combinatorial thinking he wants to formalize into a single therapeutic candidate for broader testing.
The XPrize competition David's targeting — MIT Tech Review points specifically toward Longevity Challenge platforms - rewards innovative, large-scale interventions and fits his mission perfectly because it forces measurable proof rather than theoretical promises. He aims to show functional rejuvenation across multiple tissues with consistent results instead of marginal gains in just one or two biomarkers, which would be a paradigm shift for how the longevity community thinks about drug development. The XPrize structure is ideal because it's designed for high-risk/high-reward science, and Sinclair's whole-body approach embodies that exactly — it could fundamentally change where biotech investment flows in this space if he can prove systemic reversal works at scale. I follow his lab closely through their published work and the MIT Tech Review consistently highlights how aggressive and forward-thinking they are compared to more conservative pharma teams; if this move pans out, it's not just another longevity drug — it's a different way of thinking about age as a treatable condition altogether.
Source: https://www.technologyreview.com/2026/06/09/1138545/david-sinclair-plans-to-test-whole-body-rejuvenation-drugs-in-the-xprize-competition/
The XPrize competition David's targeting — MIT Tech Review points specifically toward Longevity Challenge platforms - rewards innovative, large-scale interventions and fits his mission perfectly because it forces measurable proof rather than theoretical promises. He aims to show functional rejuvenation across multiple tissues with consistent results instead of marginal gains in just one or two biomarkers, which would be a paradigm shift for how the longevity community thinks about drug development. The XPrize structure is ideal because it's designed for high-risk/high-reward science, and Sinclair's whole-body approach embodies that exactly — it could fundamentally change where biotech investment flows in this space if he can prove systemic reversal works at scale. I follow his lab closely through their published work and the MIT Tech Review consistently highlights how aggressive and forward-thinking they are compared to more conservative pharma teams; if this move pans out, it's not just another longevity drug — it's a different way of thinking about age as a treatable condition altogether.
Source: https://www.technologyreview.com/2026/06/09/1138545/david-sinclair-plans-to-test-whole-body-rejuvenation-drugs-in-the-xprize-competition/